Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Detection and Diagnosis of Cardiac Amyloidosis in Egypt

Detection and Diagnosis of Cardiac Amyloidosis in Egypt Cardiac amyloidosis is a life-threatening disease that occurs when amyloid proteins, most commonly immunoglobulin light chain or transthyretin, mutate or become unstable, misfold, deposit as amyloid fibrils, and accumulate in the myocardium. Early diagnosis of cardiac amyloidosis is hindered by insufficient awareness, specifically regarding clinical red flags and diagnostic pathways. Cardiac amyloidosis diagnosis comprises two important phases, clinical suspicion (phase one) followed by definitive diagnosis (phase two). Each phase is associated with specific clinical techniques. For example, clinical features, electrocardiography, echocardiography, and cardiac magnetic resonance imaging serve to raise suspicion of cardiac amyloidosis and facilitate early diagnosis, whereas laboratory tests (i.e., blood or urine electrophoresis with immunofixation), biopsy, scintigraphy-based nuclear imaging, and genetic testing provide a definitive diagnosis of cardiac amyloidosis. In Egypt, both the lack of cardiac amyloidosis awareness amongst healthcare providers and the unavailability of clinical expertise for the use of diagnostic techniques must be overcome to improve the prognosis of cardiac amyloidosis in the region. Previously published diagnostic algorithms for cardiac amyloidosis have amalgamated techniques that can raise clinical suspicions of cardiac amyloidosis with those that definitively diagnose cardiac amyloidosis. Though such algorithms have been successful in developed countries, diagnostic tools like echocardiography, scintigraphy, and cardiac magnetic resonance imaging are not ubiquitously available across Egyptian facilities. This review presents the current state of knowledge regarding cardiac amyloidosis in Egypt and outlines a new diagnostic algorithm which leverages regional nuclear imaging expertise. Importantly, the proposed diagnostic algorithm guides accurate amyloid-typing to mitigate misdiagnosis and erroneous treatment selection and improve the cardiac amyloidosis diagnostic accuracy in Egypt. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Detection and Diagnosis of Cardiac Amyloidosis in Egypt

Download PDF
17 pages

Loading next page...
 
/lp/springer-journals/detection-and-diagnosis-of-cardiac-amyloidosis-in-egypt-CwO6INltZ5
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2023
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-022-00299-x
Publisher site
See Article on Publisher Site

Abstract

Cardiac amyloidosis is a life-threatening disease that occurs when amyloid proteins, most commonly immunoglobulin light chain or transthyretin, mutate or become unstable, misfold, deposit as amyloid fibrils, and accumulate in the myocardium. Early diagnosis of cardiac amyloidosis is hindered by insufficient awareness, specifically regarding clinical red flags and diagnostic pathways. Cardiac amyloidosis diagnosis comprises two important phases, clinical suspicion (phase one) followed by definitive diagnosis (phase two). Each phase is associated with specific clinical techniques. For example, clinical features, electrocardiography, echocardiography, and cardiac magnetic resonance imaging serve to raise suspicion of cardiac amyloidosis and facilitate early diagnosis, whereas laboratory tests (i.e., blood or urine electrophoresis with immunofixation), biopsy, scintigraphy-based nuclear imaging, and genetic testing provide a definitive diagnosis of cardiac amyloidosis. In Egypt, both the lack of cardiac amyloidosis awareness amongst healthcare providers and the unavailability of clinical expertise for the use of diagnostic techniques must be overcome to improve the prognosis of cardiac amyloidosis in the region. Previously published diagnostic algorithms for cardiac amyloidosis have amalgamated techniques that can raise clinical suspicions of cardiac amyloidosis with those that definitively diagnose cardiac amyloidosis. Though such algorithms have been successful in developed countries, diagnostic tools like echocardiography, scintigraphy, and cardiac magnetic resonance imaging are not ubiquitously available across Egyptian facilities. This review presents the current state of knowledge regarding cardiac amyloidosis in Egypt and outlines a new diagnostic algorithm which leverages regional nuclear imaging expertise. Importantly, the proposed diagnostic algorithm guides accurate amyloid-typing to mitigate misdiagnosis and erroneous treatment selection and improve the cardiac amyloidosis diagnostic accuracy in Egypt.

Journal

Cardiology and Therapy – Springer Journals

Published: Mar 1, 2023

Keywords: Cardiac amyloidosis; Diagnosis and subtyping; Algorithm; Electrocardiography; Echocardiography; Immunoelectrophoresis; Scintigraphy; Cardiac MRI; Endomyocardial biopsy; Egypt

References

  • Transthyretin (TTR) cardiac amyloidosis
    Ruberg, FL; Berk, JL
  • Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy
    Maurer, MS; Schwartz, JH; Gundapaneni, B; Elliott, PM; Merlini, G; Waddington-Cruz, M
  • Cardiac amyloidosis
    Martinez-Naharro, A; Hawkins, PN; Fontana, M
  • Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
    Garcia-Pavia, P; Rapezzi, C; Adler, Y; Arad, M; Basso, C; Brucato, A
  • Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope
    Gonzalez-Lopez, E; Lopez-Sainz, A; Garcia-Pavia, P
  • Cardiac amyloidosis: Evolving diagnosis and management: a scientific statement from the American Heart Association
    Kittleson, MM; Maurer, MS; Ambardekar, AV; Bullock-Palmer, RP; Chang, PP; Eisen, HJ
  • Restrictive atrial dysfunction in cardiac amyloidosis: differences between immunoglobulin light chain and transthyretin cardiac amyloidosis patients
    Versteylen, MO; Brons, M; Teske, AJ; Oerlemans, M
  • Daratumumab-based treatment for immunoglobulin light-chain amyloidosis
    Kastritis, E; Palladini, G; Minnema, MC; Wechalekar, AD; Jaccard, A; Lee, HC
  • Cardiac amyloidosis: an update on diagnosis and treatment
    Donnelly, JP; Hanna, M
  • Prevalence and risk factors of cardiac amyloidosis in heart failure: a systematic review and meta-analysis
    See, ASY; Ho, JS-Y; Chan, MY; Lim, YC; Yeo, T-C; Chai, P
  • Cardiac amyloidosis: the need for early diagnosis
    Oerlemans, M; Rutten, KHG; Minnema, MC; Raymakers, RAP; Asselbergs, FW; de Jonge, N
  • Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response
    Grogan, M; Dispenzieri, A; Gertz, MA
  • Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018
    Gertz, MA
  • Carpal tunnel syndrome: a potential early, red-flag sign of amyloidosis
    Donnelly, JP; Hanna, M; Sperry, BW; Seitz, WH
  • Diagnosis and treatment of cardiac amyloidosis: Position statement of the German Cardiac Society (DGK)
    Yilmaz, A; Bauersachs, J; Bengel, F; Buchel, R; Kindermann, I; Klingel, K
  • Diagnosing cardiac amyloidosis in every-day practice: a practical guide for the cardiologist
    Papathanasiou, M; Carpinteiro, A; Rischpler, C; Hagenacker, T; Rassaf, T; Luedike, P
  • JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis
    Kitaoka, H; Izumi, C; Izumiya, Y; Inomata, T; Ueda, M; Kubo, T
  • Nonbiopsy diagnosis of cardiac transthyretin amyloidosis
    Gillmore, JD; Maurer, MS; Falk, RH; Merlini, G; Damy, T; Dispenzieri, A
  • Epidemiologic and survival trends in amyloidosis, 1987–2019
    Ravichandran, S; Lachmann, HJ; Wechalekar, AD
  • Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among Fee-for-Service Medicare beneficiaries in the United States
    Gilstrap, LG; Dominici, F; Wang, Y; El-Sady, MS; Singh, A; Di Carli, MF
  • Physician knowledge and awareness about cardiac amyloidosis in the Middle East and Gulf region
    Al Badarin, F; Al-Humood, K; Bader, F; Alsaid, S; Sulaiman, K; Alzadjali, M
  • Established and candidate transthyretin amyloidosis variants identified in the Saudi population by data mining
    Abouelhoda, M; Mohty, D; Alayary, I; Meyer, BF; Arold, ST; Fadel, BM
  • Global epidemiology of amyloid light-chain amyloidosis
    Kumar, N; Zhang, NJ; Cherepanov, D; Romanus, D; Hughes, M; Faller, DV
  • Baseline ECG features and arrhythmic profile in transthyretin versus light chain cardiac amyloidosis
    Cappelli, F; Vignini, E; Martone, R; Perlini, S; Mussinelli, R; Sabena, A
  • Echocardiography and survival in light chain cardiac amyloidosis
    Siddiqi, OK; Sanchorawala, V; Ruberg, FL
  • Re-definition of the epidemiology of cardiac amyloidosis
    Rossi, M; Varrà, GG; Porcari, A; Saro, R; Pagura, L; Lalario, A
  • Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
    Staron, A; Zheng, L; Doros, G; Connors, LH; Mendelson, LM; Joshi, T
  • Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years
    Ioannou, A; Patel, RK; Razvi, Y; Porcari, A; Sinagra, G; Venneri, L
  • From clinical clues to final diagnosis: the return of detective work to clinical medicine in cardiac amyloidosis
    Sabbour, H; Hasan, KY; Al Badarin, F; Alibazoglu, H; Rivard, AL; Romany, I
  • Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study
    Tanskanen, M; Peuralinna, T; Polvikoski, T; Notkola, IL; Sulkava, R; Hardy, J
  • Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study
    Reilly, MM; Staunton, H; Harding, AE
  • Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
    Damy, T; Kristen, AV; Suhr, OB; Maurer, MS; Planté-Bordeneuve, V; Yu, C-R
  • Hereditary transthyretin amyloidosis from a Scandinavian perspective
    Suhr, OB; Svendsen, IH; Andersson, R; Danielsson, A; Holmgren, G; Ranlov, PJ
  • Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure
    Gagliardi, C; Perfetto, F; Lorenzini, M; Ferlini, A; Salvi, F; Milandri, A
  • Amyloidosis due to TTR mutations in Mexico with 4 distinct genotypes in the index cases
    González-Duarte, A; Cárdenas-Soto, K; Bañuelos, CE; Fueyo, O; Dominguez, C; Torres, B
  • Chinese familial transthyretin amyloidosis with vitreous involvement is associated with the transthyretin mutation Gly83Arg: a case report and literature review
    Yin, J; Xia, X; Shi, Y; Lu, Y; Zhao, C; Huang, Z
  • Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations
    Conceição, I; Damy, T; Romero, M; Galán, L; Attarian, S; Luigetti, M
  • Light chain amyloidosis: patient experience survey from the amyloidosis research consortium
    Lousada, I; Comenzo, RL; Landau, H; Guthrie, S; Merlini, G
  • Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology
    Maurer, MS
  • Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021
    Hasib Sidiqi, M; Gertz, MA
  • Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types
    Rapezzi, C; Merlini, G; Quarta, CC; Riva, L; Longhi, S; Leone, O
  • Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement
    Murtagh, B; Hammill, SC; Gertz, MA; Kyle, RA; Tajik, AJ; Grogan, M
  • Cardiac amyloidosis: updates in diagnosis and management
    Mohty, D; Damy, T; Cosnay, P; Echahidi, N; Casset-Senon, D; Virot, P
  • Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value
    Cipriani, A; Michieli, LD; Porcari, A; Licchelli, L; Sinigiani, G; Tini, G
  • How to image cardiac amyloidosis: a practical approach
    Dorbala, S; Cuddy, S; Falk, RH
  • Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study: reply
    Miller, F; Bellavia, D
  • Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis
    Feng, D; Syed, IS; Martinez, M; Oh, JK; Jaffe, AS; Grogan, M
  • Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques
    Aljaroudi, WA; Desai, MY; Tang, WH; Phelan, D; Cerqueira, MD; Jaber, WA
  • Advanced cardiac amyloidosis associated with normal interventricular septal thickness: an uncommon presentation of infiltrative cardiomyopathy
    Suresh, R; Grogan, M; Maleszewski, JJ; Pellikka, PA; Hanna, M; Dispenzieri, A
  • Endomyocardial biopsy-proven light chain amyloidosis (AL) without echocardiographic features of infiltrative cardiomyopathy
    Gertz, MA; Grogan, M; Kyle, RA; Tajik, AJ
  • Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy
    Nakahashi, T; Arita, T; Yamaji, K; Inoue, K; Yokota, T; Hoshii, Y
  • Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings
    Vergaro, G; Aimo, A; Barison, A; Genovesi, D; Buda, G; Passino, C
  • Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis
    Zhao, L; Tian, Z; Fang, Q
  • Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy
    Vogelsberg, H; Mahrholdt, H; Deluigi, CC; Yilmaz, A; Kispert, EM; Greulich, S
  • Multimodality imaging in cardiac amyloidosis: a primer for cardiologists
    Jurcut, R; Onciul, S; Adam, R; Stan, C; Coriu, D; Rapezzi, C
  • Myocardial edema and prognosis in amyloidosis
    Kotecha, T; Martinez-Naharro, A; Treibel, TA; Francis, R; Nordin, S; Abdel-Gadir, A
  • Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis
    Syed, IS; Glockner, JF; Feng, D; Araoz, PA; Martinez, MW; Edwards, WD
  • A review of the criteria for non-invasive diagnosis of cardiac transthyretin amyloidosis
    Rezk, T; Fontana, M; Gillmore, JD
  • Assessment of pharmacokinetic, pharmacodynamic profile, and tolerance of gadopiclenol, a new high relaxivity GBCA, in healthy subjects and patients with brain lesions (phase I/IIa study)
    Hao, J; Bourrinet, P; Desché, P
  • Cardiovascular magnetic resonance for amyloidosis
    Fontana, M; Chung, R; Hawkins, PN; Moon, JC
  • Quantification of extracellular matrix expansion by CMR in infiltrative heart disease
    Mongeon, F-P; Jerosch-Herold, M; Coelho-Filho, OR; Blankstein, R; Falk, RH; Kwong, RY
  • Knowledge of clinical presentation and diagnostic pathways for cardiac amyloidosis among physicians in the Middle East-Gulf region: on behalf of the Gulf Cardiac Amyloidosis Working Group
    Al Badarin, F; Al Ali, J; Bader, F; Shehab, AM; Al Said, S; Sulaiman, K
  • Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine
    Palladini, G; Russo, P; Bosoni, T; Verga, L; Sarais, G; Lavatelli, F
  • Amyloidosis of the heart and respiratory system
    Van Geluwe, F; Dymarkowski, S; Crevits, I; De Wever, W; Bogaert, J
  • The diagnostic challenges of cardiac amyloidosis: a practical approach to the two main types
    Varga, C; Dorbala, S; Lousada, I; Polydefkis, MJ; Wechalekar, A; Maurer, MS
  • Endomyocardial biopsy in the clinical context: current indications and challenging scenarios
    Porcari, A; Baggio, C; Fabris, E; Merlo, M; Bussani, R; Perkan, A
  • Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data
    Pueyo, CL; Arregui, MÁA; Gutierrez, AG; Juana, EB; Guillén, SM
  • An unusual case of cardiac amyloidosis
    Garibaldi, B; Zaas, D
  • Amyloidosis: pathogenesis and new therapeutic options
    Merlini, G; Seldin, DC; Gertz, MA
  • 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses
    Bokhari, S; Castaño, A; Pozniakoff, T; Deslisle, S; Latif, F; Maurer, MS
  • Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis
    Maurer, MS; Elliott, P; Comenzo, R; Semigran, M; Rapezzi, C
  • Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis
    Geller, HI; Singh, A; Alexander, KM; Mirto, TM; Falk, RH
  • Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release
    Sperry, BW; Reyes, BA; Ikram, A; Donnelly, JP; Phelan, D; Jaber, WA
  • Carpal tunnel syndrome in transthyretin cardiac amyloidosis: Implications and protocol for diagnosis and treatment
    Boyle, RP; Sharan, J; Schwartz, G
  • Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
    Kumar, S; Dispenzieri, A; Lacy, MQ; Hayman, SR; Buadi, FK; Colby, C
  • A new staging system for cardiac transthyretin amyloidosis
    Gillmore, JD; Damy, T; Fontana, M; Hutchinson, M; Lachmann, HJ; Martinez-Naharro, A
  • Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system
    Grogan, M; Scott, CG; Kyle, RA; Zeldenrust, SR; Gertz, MA; Lin, G
  • Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment
    Siddiqi, OK; Ruberg, FL
  • Position statement on diagnosis and treatment of cardiac amyloidosis—2021
    Simões, MV; Fernandes, F; Marcondes-Braga, FG; Scheinberg, P; Correia, EDB; Rohde, LEP
  • Natural history and therapy of AL cardiac amyloidosis
    Grogan, M; Dispenzieri, A
  • Myocardial contraction fraction by M-mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis
    Rubin, J; Steidley, DE; Carlsson, M; Ong, M-L; Maurer, MS
  • Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis
    Castano, A; Haq, M; Narotsky, DL; Goldsmith, J; Weinberg, RL; Morgenstern, R
  • Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis
    Fontana, M; Pica, S; Reant, P; Abdel-Gadir, A; Treibel, TA; Banypersad, SM
  • Survey conducted at an academic medical center revealed knowledge gaps of transthyretin amyloidosis cardiomyopathy predominantly in primary care providers
    Raichlin, E; Sagalovich, M